A detailed history of Core Alternative Capital transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Core Alternative Capital holds 131 shares of VRTX stock, worth $53,471. This represents 0.01% of its overall portfolio holdings.

Number of Shares
131
Previous 131 -0.0%
Holding current value
$53,471
Previous $61,000 1.64%
% of portfolio
0.01%
Previous 0.01%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$407.69 - $446.08 $19,976 - $21,857
49 Added 59.76%
131 $54,000
Q4 2023

Feb 14, 2024

SELL
$343.0 - $410.68 $37,387 - $44,764
-109 Reduced 57.07%
82 $33,000
Q3 2023

Oct 19, 2023

BUY
$338.18 - $362.46 $35,508 - $38,058
105 Added 122.09%
191 $66,000
Q2 2023

Jul 27, 2023

SELL
$314.42 - $351.91 $9,747 - $10,909
-31 Reduced 26.5%
86 $30,000
Q1 2023

Apr 18, 2023

BUY
$283.23 - $323.1 $12,178 - $13,893
43 Added 58.11%
117 $36,000
Q2 2022

Aug 01, 2022

BUY
$234.96 - $292.55 $6,108 - $7,606
26 Added 54.17%
74 $21,000
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $5,756 - $6,785
26 Added 118.18%
48 $13,000
Q4 2021

Feb 11, 2022

BUY
$177.01 - $223.45 $3,894 - $4,915
22 New
22 $5,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Core Alternative Capital Portfolio

Follow Core Alternative Capital and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Core Alternative Capital, based on Form 13F filings with the SEC.

News

Stay updated on Core Alternative Capital with notifications on news.